-
Sinopharm: Medical Device Annual Revenue Announcement
Time of Update: 2021-03-27
Facing the national centralized procurement, the latest strategy is announced According to the announcement of Sinopharm Holdings, in 2020, the strict prevention and control measures adopted by hospitals will restrict the development of daily medical operations and hospitalization services, which will have a phased impact on the sales and product structure of the medical device business.
-
Dongyangguang: Application for drug registration of insulin aspart injection has been accepted
Time of Update: 2021-03-27
(hereinafter referred to as "Dongyang Pharmaceutical") insulin aspart injection had received the "Notice of Acceptance" issued by the State Food and Drug Administration.
According to Ai Kunwei data, in 2019, China's diabetes drug sales amount is approximately 3.
-
Eli Lilly's basal insulin BIF has a hypoglycemic effect comparable to Novo Nordisk insulin
Time of Update: 2021-03-27
CompilenewbornAccording to a phase 2 clinical trial (NCT03736785), a new once-a-week basal insulin injection has similar efficacy and safety compared with once-a-day basal insulin, and has a lower incidence of hypoglycemia.
-
Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation
Time of Update: 2021-03-27
("Shandong Luoxin") had recently received the approval and issue of Ogilvy for Injection from the National Medical Products Administration.
The omeprazole sodium for injection developed by Shandong Luoxin was first approved for marketing in 2005.
-
Application of Dominant Fragment Hybridization Strategy in Drug Development
Time of Update: 2021-03-27
Later, through molecular docking and hybridization strategies of dominant fragments, other researchers discovered that new pyridine amide and pyridone derivatives have strong inhibitory activity against HIV.
-
Procon Health Technology and Hutchison Medical reach clinical cooperation
Time of Update: 2021-03-27
Source: Guanlan PharmaceuticalOn February 23, Convalife announced that it has reached a clinical cooperation with Hutchison Pharmaceuticals to evaluate the high selection of PARP inhibitors Mefurpiride and Hutchison Pharmaceuticals with "best-in-class" potential for approval for listing The safety and tolerability of Fruquintinib combined with the treatment of solid tumors.
-
The best pharmaceutical companies in the hearts of American employees: Horizon, Genentech, and AbbVie are among the top three
Time of Update: 2021-03-27
In this year's industry survey, GreatPlacetoWork compiled the annual ranking of Fortune by using an anonymous survey of more than 825,000 employees from the US medical and pharmaceutical industries.
"Reference source: Horizon, Roche's Genentech, AbbVie and Neurocrine rank as top pharma places to work in annual poll
-
Indian Prime Minister Modi vaccinated the first dose of the new crown vaccine, which was developed locally in India
Time of Update: 2021-03-27
Modi said that through the efforts of Indian doctors and scientists, India was able to quickly develop a vaccine and strongly supported the global fight against the new crown pneumonia epidemic.
-
Why is there little news about the gradual launch of new crown vaccines?
Time of Update: 2021-03-27
From the end of 2020 to the present for more than two months, a variety of new crown vaccines have been approved for marketing worldwide, and large-scale vaccination has begun in China, the United States, Russia, Brazil, Southeast Asia, the Middle East and other countries and regions for the global economy and society The restoration of order brought dawn.
-
Five new drugs are planned to be breakthrough therapies from Junshi, Microchip, Novo Nordisk...
Time of Update: 2021-03-27
include:Junshi Biologics' PD-1 Teriprizumab is used in the first-line treatment of mucosal melanoma;Novo Nordisk's long-acting GLP-1 inhibitor Semaglutide (Semaglutide) is used in the treatment of NASH;The first class of Microchip's new drug Cioroni is used in the treatment of ovarian cancer;Yuheng Bio/WuXi Biologics PD-1 monoclonal antibody Sepalizumab (GLS-010) is used in the treatment of cervical cancer;Shanghai Ruixing's oxynidone capsule is used for chronic hepatitis B fibrosis.
-
AstraZeneca's CLL drug Calquence is approved by NICE in the UK
Time of Update: 2021-03-27
CompilationFan DongdongA few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
-
Fuan Pharmaceutical: Cefminox sodium for injection passed the consistency evaluation
Time of Update: 2021-03-27
, has recently received a supplementary drug application approval notice issued by the National Medical Products Administration, and its product Cefminox sodium for injection has passed The quality and efficacy consistency evaluation of generic drugs.
Cefminox sodium for injection is an anti-infective drug.
-
AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine
Time of Update: 2021-03-27
The Data Safety Monitoring Committee found no increased risk of thrombosis in 21,583 subjects who received at least one dose of the vaccine, and no CVST event was found in this clinical trial.
-
Osaikang Pharmaceutical's dexrazoxane for injection has been approved
Time of Update: 2021-03-27
On March 17, the official website of the State Administration of Food and Drug Administration showed that Jiangsu Aosaikang Pharmaceutical's dexrazoxane for injection was approved for listing in imitation 3 categories, and it was deemed to have been reviewed.
-
A pharmaceutical company was warned for failing to comply with GMP during the inspection process
Time of Update: 2021-03-27
Violation of "Pharmaceutical Production Quality Management Regulations"The on-site inspection of Fujian Minghua Pharmaceutical Co.
-
Where is the next leap in CAR-T therapy? Cinda Bio and other Chinese companies explore new directions
Time of Update: 2021-03-27
According to the official website of Reindeer Medical, for patients with relapsed/refractory multiple myeloma, high-dose BCMA targeted CAR-T cell therapy may provide better remission, but the adverse events are more serious.
-
The new requirements of the Health Commission affect a large number of secondary hospitals!
Time of Update: 2021-03-27
The "Task" clarified that, in order to improve the mental health service capabilities of medical institutions, 100% psychiatric hospitals in the pilot area have set up mental outpatient clinics, and 40% of general hospitals above the second level open mental (psychological) outpatient clinics.
-
Sanofi/Dupixent, a new pediatric asthma drug, enters review in the U.S.
Time of Update: 2021-03-27
S. Food and Drug Administration (FDA) has accepted the anti-inflammatory drug Dupixent (Chinese trade name: Dabituo, generic name: dupilumab, dupilumab) ) A supplementary biological product license (sBLA), as an add-on therapy for the treatment of children with moderate to severe asthma who are 6-11 years old and whose condition is uncontrolled.
-
The National Health Commission released the second batch of catalogs of encouraged generic drugs containing 17 varieties
Time of Update: 2021-03-27
On March 15, the National Health Commission, together with the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the National Medical Insurance Administration, the National Food and Drug Administration, and the State Intellectual Property Office, organized experts to report on the imminent expiration of domestic patents and the lack of clinical supply.
-
CDE intends to identify Hengrui CDK4/6 inhibitors and Junshi anti-PD-1 for breakthrough therapy
Time of Update: 2021-03-27
In August 2019, Junshi announced the results of an open-label phase IB clinical trial of teriprizumab combined with the anti-angiogenic drug axitinib for the treatment of advanced mucosal melanoma.
